Lapstone & Hammer Expands ASICS 'Dip Dye' Series with Beverage-Inspired Colorways 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
ECB Calls for Monitoring and Possible Regulation of AI in Finance 
Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Skepta and PUMA Launch Groundbreaking Collection 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
McDonald's China Faces Backlash for Food Hygiene Violations 
ALWAYTH x Adidas Samba: Revolutionizing Sneaker Culture with Fashion-Forward Collaboration 
 Securities Case - EconoTimes)
NEW YORK, March 09, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email [email protected] to discuss their legal rights.
About the Lawsuit
Esperion is a pharmaceutical company that focuses on developing and commercializing oral low-density lipoprotein cholesterol ("LDL-cholesterol") lowering therapies. The securities lawsuit alleges that Esperion issued a press release on August 17, 2015 about its lead product candidate, ETC-1002, that was false and was in conflict with a September 28, 2015 press release.
On August 17, 2015, Esperion stated that it "remains on track to initiate the ETC-1002 Phase 3 development program by the end of 2015" and that, "[b]ased on feedback from the FDA, approval of ETC-1002 in the HeFH and ASCVD patient populations will not require the completion of a cardiovascular outcomes trial (CVOT)."
On September 28, 2015, Esperion stated that "[f]or patients on maximally tolerated statin therapy who require additional LDL-C lowering, Esperion will plan to conduct efficacy and long-term safety trials. FDA has encouraged the Company to initiate a cardiovascular outcomes trial promptly … since any concern regarding the benefit/risk assessment of ETC-1002 could necessitate a completed cardiovascular outcomes trial before approval."
On this news, shares of the Company's stock declined $16.76 per share, or over 47%, to close on September 29, 2015 at $18.33 per share.
What you can do
If you purchased shares of Esperion stock, you may have legal claims against the Company. If you wish to discuss the investigation, or have questions about your legal rights, please contact Geoffrey M. Johnson, Esq. or Joseph Halloran, Esq. by telephone at (866) 326-5057 or by email at [email protected] or [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio.
CONTACT:
Geoffrey M. Johnson, Esq.
Joseph Halloran, Esq.
(216) 229-6088, toll-free (866) 326-5057
[email protected]
[email protected]
